ABHIMANYU GARG, MD
Osteopathic Medicine at Harry Hines Blvd, Dallas, TX
License number
Texas H3351
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
5323 Harry Hines Blvd, Dallas, TX 75390
Phone
(214) 645-0624
(214) 645-0078 (Fax)
(214) 645-0078 (Fax)
Personal information
See more information about ABHIMANYU GARG at radaris.comName
Address
Phone
4802 Dorset Rd, Dallas, TX 75229
4802 Dorset Rd, Dallas, TX 75229
Organization information
See more information about ABHIMANYU GARG at bizstanding.comAbhimanyu Garg MD,MBBS
5323 Harry Hines Blvd STOP 8537, Dallas, TX 75390
Industry:
Genetic Medicine, Internist
Phone:
(214) 645-0624 (Phone)
Abhimanyu Garg
Professional information
Abhimanyu Garg, Dallas TX
Specialties:
Internist
Address:
5323 Harry Hines Blvd, Dallas, TX 75390
Education:
All-India Institute of Medical Sciences - Doctor of Medicine
University of Alabama Hospital - Fellowship - Endocrinology, Diabetes, and Metabolism (Internal Medicine)
All India Institute of Medical Sciences - Residency - Internal Medicine
All India Institute of Medical Sciences - Internship - Rotating
University of Alabama Hospital - Fellowship - Endocrinology, Diabetes, and Metabolism (Internal Medicine)
All India Institute of Medical Sciences - Residency - Internal Medicine
All India Institute of Medical Sciences - Internship - Rotating
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Endocrinology, Diabetes, and Metabolism (Internal Medicine)
Dr. Abhimanyu Garg, Dallas TX - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism
Address:
UT Intrnl Med Sub Speclty Clin
5303 Harry Hines Blvd #Suite U8.400, Dallas 75390
(214) 645-2800 (Phone)
5303 Harry Hines Blvd #Suite U8.400, Dallas 75390
(214) 645-2800 (Phone)
Certifications:
Diabetes, Metabolism & Endocrinology, 2011, Internal Medicine, 1989
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
UT Intrnl Med Sub Speclty Clin
5303 Harry Hines Blvd #Suite U8.400, Dallas 75390
Ut Southwestern University Hospital
5909 Harry Hines Blvd, Dallas 75390
Ut Southwestern University Hospital - Zale Lipshy
5151 Harry Hines Blvd, Dallas 75235
5303 Harry Hines Blvd #Suite U8.400, Dallas 75390
Ut Southwestern University Hospital
5909 Harry Hines Blvd, Dallas 75390
Ut Southwestern University Hospital - Zale Lipshy
5151 Harry Hines Blvd, Dallas 75235
Education:
Medical School
All-India Institute of Medical Science / Ansari Nagar
All India Inst Med Scis
U Ala Birmingham
All-India Institute of Medical Science / Ansari Nagar
All India Inst Med Scis
U Ala Birmingham
Professor At Ut Southwestern
Position:
Professor at UT Southwestern
Location:
Dallas/Fort Worth Area
Industry:
Medical Practice
Work:
UT Southwestern
-
Professor
Use Of Leptin For Treating Human Lipoatrophy And Method Of Determining Predisposition To Said Treatment
US Patent:
2007009, May 3, 2007
Filed:
Nov 29, 2006
Appl. No.:
11/606805
Inventors:
Alexander DePaoli - Santa Barbara CA, US
Simeon Taylor - Skillman NJ, US
Elif Oral - Ann Arbor MI, US
Abhimanyu Garg - Dallas TX, US
Simeon Taylor - Skillman NJ, US
Elif Oral - Ann Arbor MI, US
Abhimanyu Garg - Dallas TX, US
Assignee:
Amgen, Inc. - Thousand Oaks CA
The Govt. of the U.S.A. as represented by the Secretary, Dept. of Health & Human Services - Rockville MD
Board of Regents, The University of Texas System - Austin TX
The Govt. of the U.S.A. as represented by the Secretary, Dept. of Health & Human Services - Rockville MD
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 38/17
US Classification:
514012000
Abstract:
Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.
Use Of Leptin To Treat Metabolic Abnormalities Associated With Lipoatrophy
US Patent:
8318666, Nov 27, 2012
Filed:
May 9, 2011
Appl. No.:
13/103294
Inventors:
Alexander M. DePaoli - Santa Barbara CA, US
Elif Arioglu Oral - Ann Arbor MI, US
Simeon I. Taylor - Skillman NJ, US
Abhimanyu Garg - Dallas TX, US
Elif Arioglu Oral - Ann Arbor MI, US
Simeon I. Taylor - Skillman NJ, US
Abhimanyu Garg - Dallas TX, US
Assignee:
Amgen, Inc. - Thousand Oaks CA
The United States of America, as Represented by the Secretary, Department of Health and Human Services - Washington DC
Board of Regents, The University of Texas System - Austin TX
The United States of America, as Represented by the Secretary, Department of Health and Human Services - Washington DC
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 38/00, A61K 38/22, A61P 3/06
US Classification:
514 58, 514 74
Abstract:
Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.
Use Of Leptin For Treating Human Lipoatrophy And Method Of Determining Predisposition To Said Treatment
US Patent:
2005002, Jan 27, 2005
Filed:
Jul 18, 2003
Appl. No.:
10/623189
Inventors:
Alexander DePaoli - Santa Barbara CA, US
Simeon Taylor - Skillman NJ, US
Elif Oral - Ann Arbor MI, US
Abhimanyu Garg - Dallas TX, US
Simeon Taylor - Skillman NJ, US
Elif Oral - Ann Arbor MI, US
Abhimanyu Garg - Dallas TX, US
International Classification:
A61K038/17
US Classification:
514012000
Abstract:
Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.
Use Of Leptin For Treating Human Lipoatrophy And Method Of Determining Predisposition To Said Treatment
US Patent:
2013019, Jul 25, 2013
Filed:
Nov 5, 2012
Appl. No.:
13/669324
Inventors:
Alexander M. DePaoli - Santa Barbara CA, US
Elif Ariogiu Oral - Ann Arbor MI, US
Simeon I. Taylor - Skillman NJ, US
Abhimanyu Garg - Dallas TX, US
Elif Ariogiu Oral - Ann Arbor MI, US
Simeon I. Taylor - Skillman NJ, US
Abhimanyu Garg - Dallas TX, US
International Classification:
A61K 38/22, G01N 33/68
US Classification:
514 19, 514 58, 53038824, 5303892, 435 792
Abstract:
Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.